Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis
Status:
Active, not recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Spastic paraparesis is one of the most disabling functional deficits in the population with
multiple sclerosis between 18 and 80 years of age and at any functional level. Infiltration
with Botulinum Toxin is a clinical practice that has been carried out for years with clinical
evidence of improvement in the patient's walking patterns and quality of life. We assume that
the infiltration of this product can generate a direct benefit in the walking ability of
these patients and secondarily improve their quality of life.
Phase:
Phase 3
Details
Lead Sponsor:
Aránzazu Vázquez Doce
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A